Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0302 | -4.87096774194 | 0.62 | 0.62 | 0.5771 | 200969 | 0.59718425 | CS |
4 | -0.2085 | -26.1180007516 | 0.7983 | 0.8279 | 0.56 | 377376 | 0.68973857 | CS |
12 | -1.0902 | -64.8928571429 | 1.68 | 3.44 | 0.542 | 1057506 | 1.22187338 | CS |
26 | -1.2802 | -68.4598930481 | 1.87 | 3.44 | 0.542 | 561530 | 1.33379117 | CS |
52 | -0.6702 | -53.1904761905 | 1.26 | 3.44 | 0.542 | 377575 | 1.44528058 | CS |
156 | -11.5602 | -95.1456790123 | 12.15 | 13.8 | 0.542 | 234611 | 2.39219672 | CS |
260 | -11.5602 | -95.1456790123 | 12.15 | 13.8 | 0.542 | 234611 | 2.39219672 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.